ABCD : Update of the 2009 guidelines on prevention and management of feline infectious diseases by Horzinek, M.C. et al.
 http://jfm.sagepub.com/
Journal of Feline Medicine and Surgery
 http://jfm.sagepub.com/content/15/7/530
The online version of this article can be found at:
 
DOI: 10.1177/1098612X13489208
 2013 15: 530Journal of Feline Medicine and Surgery
Pennisi, Alan D Radford, Etienne Thiry and Uwe Truyen
Gruffydd-Jones, Katrin Hartmann, Margaret J Hosie, Albert Lloret, Hans Lutz, Fulvio Marsilio, Karin Möstl, Maria Grazia 
Marian C Horzinek, Diane Addie, Sándor Belák, Corine Boucraut-Baralon, Herman Egberink, Tadeusz Frymus, Tim
ABCD: Update of the 2009 guidelines on prevention and management of feline infectious diseases
 
 
technique does not amount to an endorsement of its value or quality, or the claims made by its manufacturer.
those of the authors and the inclusion in this publication of material relating to a particular product, method or 
of animals and interpretation of published materials lies with the veterinary practitioner. The opinions expressed are
from actions or decisions based on information contained in this publication; ultimate responsibility for the treatment 
arisingcountry. The authors, editors, owners and publishers do not accept any responsibility for any loss or damage 
advertising material, it is the responsibility of the reader to check that the product is authorised for use in their own
bear this in mind and be aware of the prescribing laws pertaining to their own country. Likewise, in relation to 
Furthermore, drugs may be mentioned that are licensed for human use, and not for veterinary use. Readers need to
formulations that are not available or licensed in the individual reader's own country.





 International Society of Feline Medicine
 
 American Association of Feline Practitioners
and
 http://www.sagepublications.com





 http://jfm.sagepub.com/cgi/alertsEmail Alerts: 
 





 What is This?
 
- Jun 27, 2013Version of Record >> 
 at Universite de Liege on September 3, 2013jfm.sagepub.comDownloaded from 
Feline panleukopenia
This oldest feline viral disease known to the veterinary profession is
caused by a typical parvovirus (feline panleukopenia virus, FPV) that
infects a wide variety of carnivores including all felids, mustelids, pro-
cyonids and most canids. The dog and the coyote are the only carni-
vores that will not be infected, or will not develop disease, as the
receptor on their cells will not bind the virus.1
All parvoviruses are very stable and may
stay infectious in the environment for
months. They are highly contagious,
which means that only a few virus 
particles are required to induce an
infection. As an affected animal sheds
enormous amounts of virus, soon the
shelter or household is heavily con-
taminated, which causes a threat to
non-vaccinated – or, rather, non-
immune – animals, like cats and other
carnivores.
Virus replication is restricted to mitotically
active tissues, such as the bone marrow, lymphat-
ic cells, the gut epithelium and the developing fetus. The hallmark of
infection is a viraemia, which carries the virus from the initially infect-
ed cells of the tonsils and other regional cells to the target tissues.
Neutralising antibodies can greatly influence the viraemia and are
even able to prevent virus spread through the organism. Animals that
have survived the disease are protected from reinfection, most likely
for their entire life.
Vaccination is highly efficacious, and cats that have actively respond-
ed to vaccination and show antibody titres are protected for several
years, and probably also life-long. However, the success of vaccination
is greatly influenced by neutralising antibodies. In the case of passive-
ly acquired antibodies this has severe consequences. Maternal antibod-
ies interfere with vaccination, and the time-point of the first
vaccination is therefore important. To minimise the risk of this interfer-
ence, kittens are vaccinated twice or even three times during their first
weeks of life. 
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Overview: In this article, the ABCD guidelines
published in the JFMS Special Issue of July 2009
(Volume 11, Issue 7, pages 527–620) are updated 
by including previously unavailable and novel
information. For a better picture, the reader is
advised to consult that issue before focusing 
on the novel features. 
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The feline panleukopenia guidelines that
this present article is updating were
published in J Feline Med Surg 2009; 11:
538–546. This update has been compiled by 
Uwe Truyen. 
European Advisory Board on Cat Diseases
The European Advisory Board on Cat Diseases (ABCD)
is a body of experts in immunology, vaccinology 
and clinical feline medicine that issues guidelines on
prevention and management of feline infectious diseases
in Europe, for the benefit of the health and welfare of cats.
The guidelines are based on current scientific knowledge
of the diseases and available vaccines concerned.
The latest full version of the disease guidelines
updated in this article is available at 
www.abcd-vets.org
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Primary vaccination course
< A minimum of two doses – one at 8–9
weeks of age and a second 3–4 weeks later 
(at a minimum of 12 weeks of age) – should
be administered to cats living in low-risk
situations.
< In higher-risk situations, a third
vaccination, at 16 weeks, is recommended.
Maternal antibodies may persist beyond
week 12 in some cats, as field data suggest,2
such that vaccination at 12 weeks may fail to
induce protection [EBM grade 1]. Therefore, 
a third vaccination at 16 weeks of life should
be given, for example, to kittens in breeding
catteries or cat shelters. This should also be
considered for kittens born to queens with
high antibody titres, as these may persist for
more than 12 weeks (eg, kittens from queens
that have recovered from the disease, that
have lived in a high-exposure environment,
or have received vaccination shortly before or
during pregnancy). 














To clean nasal discharge
and to prevent dehydration
of the upper airways
Recommended several times daily IV
Highly palatable food To ensure sufficient food
intake 
Necessary if cats do not eat because of
pyrexia and/or ulcers in the oral cavity, 
or because of their loss of smell due to
nasal congestion; food can be blended





To ensure sufficient food
intake














Fluid therapy To control dehydration 
and restore electrolyte 
and acid–base imbalance
Necessary in cats with severe clinical signs IV
Antibiotics To control secondary
bacterial infections
Broad-spectrum antibiotics with good
penetration into the respiratory tract are










To improve mucous nasal
discharge
May be helpful IV
Symptomatic treatment for acute respiratory diseaseTable 1
Drug Rationale ABCD recommendation EBM grade







Usually not needed; avoid corticosteroids IV
Symptomatic treatment for acute ocular disease (conjunctivitis and keratitis)Table 2
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Feline herpesvirus infection
Feline herpesvirus (FHV) is the agent of feline
viral rhinotracheitis. Together with feline cali-
civirus and other pathogens, it is involved in
the feline upper respiratory tract syndrome.
Typical acute FHV disease results in rhinitis,
conjunctivitis, and superficial and deep
corneal ulcers, in particular dendritic ulcers.
Latent chronic infection is the typical outcome
of an acute infection, and reactivation gives
rise to intermittent viral shedding in
oronasal and conjunctival secretions.
Conjunctivitis may be associated
with corneal ulcers, which may
develop into chronic sequestra.
FHV is the most important cause
of corneal ulceration.3 Stromal 
keratitis is a secondary, immune-
mediated reaction due to the 
presence of virus in the epithelium
or stroma. Damage to the nasal
Feline herpesvirus
infection: ABCD guidelines on
prevention and management
The feline herpesvirus infection guidelines
that this present article is updating were
published in J Feline Med Surg 2009; 11:
547–555. This update has been compiled by 
Etienne Thiry. 
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Drug Type of drug Route of administration
and dose



















Use every h for 1st day 
and q4h thereafter7 
Excellent ND No Topical treatment of
choice for ocular FHV
manifestations. Some
cats averse to topical







Yes Yes Yes Topical treatment for
ocular FHV; potent drug







Excellent ND No Topical treatment for
ocular FHV. Difficult 
to source; pharmacists 






Topical Excellent ND ND Topical treatment for





Topical and oral Poor
(high doses may be
needed to overcome 
viral resistance)
Some Yes Least in vitro effect of 
all herpes antivirals10,11























is a prodrug of
penciclovir) 
Yes Yes Tested in conventional




Feline IFN-ω Interferon Systemic:




Topical: dilute 10 MU vial in
19 ml 0.9% NaCl and use
as eye drops: two drops in
each eye five times a day
for 10 days17
Yes ND Yes Safe and licensed for 
use in cats


















Less bioactive than 
feline interferon
5–35 Units daily reduces
clinical signs but not FHV
shedding. Used along
with L-lysine in chronic
infections
III
L-lysine Amino acid 500 mg q12h, not added
to food









bolus, not added to
food4,7,9,18–22
II
ND = not determined, SPF = specific pathogen-free
Antiviral drugs recommended for topical and systemic treatment of acute FHV ocular disease. 
The drugs are listed in decreasing order of preference
Table 3
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Evidence-based medicine (EBM) is a process of clinical decision-making 
that allows clinicians to find, appraise and integrate the current best 
evidence with individual clinical expertise, client wishes and patient needs. 
This article uses EBM ranking to grade the level of evidence of various state-
ments and recommendations on a scale of I to IV as follows: 
< EBM grade I This is the best evidence, comprising data obtained from
properly designed, randomised controlled clinical trials in the target
species (in this context cats);
< EBM grade II Data obtained from properly designed, randomised
controlled studies in the target species with spontaneous disease in 
an experimental setting;
< EBM grade III Data based on non-randomised clinical trials, multiple
case series, other experimental studies, and dramatic results from
uncontrolled studies;
< EBM grade IV Expert opinion, case reports, studies in other species,
pathophysiological justification. If no grade is specified, the EBM level 
is grade IV.
Further reading
Lloret A. The process of evidence-based medicine. J Feline Med Surg 2009; 11: 529.
Roudebush P, Allen TA, Dodd CE and Novotny BJ. Application of evidence-based 
medicine to veterinary clinical nutrition. J Am Vet Med Assoc 2004; 224: 1765–1771.
EBM ranking used in th is  ar t ic le
lymphoplasmacytic gingivitis/stomatitis
complex test positive for FCV. In addition,
outbreaks of highly virulent and often lethal
FCV infection in domestic cats have been
described in the United States and in Europe;
recently, a single outbreak has also been
described in exotic captive felids in the USA.
Transmission is usually through contact
with infected cats but secretions can remain
infectious in the environment for many days.
Fleas that have lived on infected cats have also
recently been shown to shed infectious faeces,
although how significant this is in the field is
unknown. Diagnosis is based on clinical signs,
supplemented by virus isolation or PCR.
Because of the frequent asymptomatic carrier
phase, care should be taken when interpreting
any FCV-positive result. 
Feline interferon-ω (licensed for the treat-
ment of canine parvovirus and feline
leukaemia virus infections in some European
countries) has been shown to inhibit FCV
replication in vitro. However, controlled field
studies are lacking to support its use in cases
of uncomplicated oral/respiratory disease.
There is also some suggestion that strains of
FCV may vary in their sensitivity to interfer-
on. In cases of chronic stomatitis, topical 
oral interferon has been shown to lead to
statistical improvement in clinical scores,
but this improvement was generally not dif-
ferent from cats receiving steroid alone
[EBM grade I].25
FCV vaccines provide protection mainly by
inducing virus neutralising antibodies. As the
virus can mutate quickly, field strains could
turbinates during acute disease is a predispos-
ing factor for chronic rhinitis.
Molecular diagnosis is now in regular use,
especially to identify FHV DNA in corneal
samples. The practitioner should avoid the
use of fluorescein and topical anaesthetics in
the eye before sampling because these com-
pounds can affect the sensitivity of some poly-
merase chain reaction (PCR) methods,4 unless
permitted by the diagnostic laboratory.
The symptomatic treatment for acute respi-
ratory disease where FHV infection may be
involved is summarised in Table 1. The symp-
tomatic treatment for acute ocular disease is
outlined in Table 2.
Anti-herpesviral drugs have come to the mar-
ket, which now allow recommendations to be
made for the topical and systemic treatment of
acute FHV ocular disease (Table 3). The drugs
listed may not be readily available or licensed
for cats. Other drugs have been proposed, like
bromovinyldeoxyuridine, HPMA, ribavirin,
valaciclovir, vidarabine, foscarnet and lacto -
ferrin, but their efficacy has not been proven.
Maternally derived (passive) immunity can
interfere with the response to vaccination
until about 8 weeks of age [EBM grade III];5
the primary vaccination course is therefore
usually started at around 9 weeks of age,
although some products are licensed for earli-
er use. Kittens should receive a second vacci-
nation 2–4 weeks later, with the second given
at around 12 weeks of age. Vaccination pro-
vides good protection against clinical signs,
and also against viral shedding, within 1 week
of administration [EBM grade III].6
FHV is common in multicat households,
and infections can pose a problem in shelters.
Management to limit the spread of infection is
as important as vaccination. In shelters where
incoming cats are mixed with resident cats,
high infection rates are frequent. Newcomers
should therefore be quarantined for the first 3
weeks, and kept individually – unless known
to come from the same household.
Feline calicivirus infection
Feline calicivirus (FCV) remains an important
cause of disease and a frequently diagnosed
infection in both ill and healthy carrier ani-
mals. The virus evolves quickly and is
very variable, particularly at antigenic
sites on its surface exposed to the
feline immune response. As such,
many strains co-circulate, even at the
level of the population of cats seen by
a typical veterinary surgery.23 As well
as causing consistent oral ulceration
and upper respiratory disease, the virus
has also been associated with superficial
ocular disease.24 Nearly all cats with chronic
Feline calicivirus
infection: ABCD guidelines on
prevention and management
The feline calicivirus infection guidelines
that this present article is updating were
published in J Feline Med Surg 2009; 11:
556–564. This update has been compiled by 
Alan D Radford. 
 at Universite de Liege on September 3, 2013jfm.sagepub.comDownloaded from 
SPEC IAL  ART ICLE / ABCD guidelines update
534 JFMS CLINICAL PRACTICE
evolve resistance to any vaccine-induced
immune response, particularly if a vaccine is
used for a prolonged period of time in the pop-
ulation. Some laboratory studies lend support
to this hypothesis [EBM grade III].26,27 Such
studies are conducted to obtain more informa-
tion about the strains circulating in Europe,
and vaccine companies are seeking to identify
newer strains that provide wider cross protec-
tion. However, the methodology used in such
studies makes it difficult to draw any firm con-
clusions from these results. In addition, there
are issues about how such laboratory studies
relate to vaccine-induced immunity in the field
situation. Field trials to show whether newer
vaccine strains confer improved protection
have not been undertaken.
The most commonly used vaccine strains of
FCV are F9, which is the oldest, isolated in the
1950s, FCV 255, and two new strains G1 and 431.
Maternally derived antibody can interfere
with vaccine-induced immunity. The higher
the level, the greater the interference. Where a
more rapid response to vaccination is
required, a modified-live vaccine may be pre-
ferred [EBM grade III].28,29 The ABCD recom-
mends that all kittens receive vaccinations at
approximately 9 and 12 weeks of age, and for
those individuals judged to live in high-risk
situations, a further vaccination at 16 weeks.
Dogs and cats in shelter or kennel environ-
ments should be housed separately, and flea
control should be implemented to minimise
the risk of transmission of FCV and other dis-
eases. Point of care assays for identifying cats
lacking protective immunity on admission to
shelters have been described,30 but their prac-
ticality is not known. They should not be used
as a replacement for rigorous biosecurity. 
Feline leukaemia
Feline leukaemia virus (FeLV) is a gamma-
retrovirus of worldwide occurrence that is
important for all small felids. Infected cats
may become persistently viraemic and shed
large amounts of virus through saliva and fae-
ces, whereby they can infect other cats in close
contact. Several variants of FeLV are known
that differ in virulence and host cell spec-
trum. As is the case for all retroviruses,
a DNA copy of replicating FeLV RNA
is integrated into the DNA of host
cells (as so-called provirus), where
it remains for the lifetime of the
infected cell. 
Infection starts in the oro -
pharynx from where the virus will
spread via leukocytes to lymph
nodes and the bone marrow. Once
the bone marrow is infected, viraemia
will develop and, as a consequence, FeLV
replication will take place in many organs. In
most cases, viraemia will be persistent and
lead to clinical signs such as aplastic anaemia,
immunosuppression and a variety of
tumours. These cats are called progressor cats.
In a fraction of infected cats, viraemia will
either not develop or will be overcome after
several weeks or months (regressor cats).
Antibodies to FeLV and/or T lymphocytes are
observed in regressor cats, suggesting that a
functioning immune system is essential.
Regressor cats remain latently infected for
some time, and viraemia can be reactivated by
stress and/or high doses of corticosteroids.
The diagnosis of FeLV infection is mostly
done by in-house tests that detect the viral
core protein p27. Presence of p27 is a marker
for infection and correlates well with
viraemia. In addition, proviral DNA can be
detected through PCR techniques in blood,
and viral RNA, eg, in saliva. Information that
can be drawn from test results is discussed in
the box above.
Treatment of viraemic cats can be tried using
raltegravir, an antiretroviral drug used in AIDS
treatment, at up to 40 mg/kg body weight per
day. Under experimental conditions, a 15-week




The feline leukaemia guidelines that this
present article is updating were published in
J Feline Med Surg 2009; 11: 565–574. This
update has been compiled by Hans Lutz. 
< The cat is positive for p27 This animal is viraemic. Cats with this result
are always also PCR-positive for provirus. Viraemic cats should be kept
separate from other cats. Given sufficient time, p27-positive cats can
revert to a negative status if they remain healthy. 
< The cat is negative for p27 This animal has either never been in contact
with FeLV or it has become immune. If it is immune, it might still be
latently infected. Latent infection can be detected by showing proviral
DNA using the PCR. Whether a PCR test should be done depends on 
the situation: a breeder with an FeLV-negative cattery who introduces a
new breeding cat may want to be certain that this animal is not latently
infected. 
< The cat gives a questionably positive test result for p27 This could
mean that it has a focus of infection somewhere in the body, which
releases low amounts of p27 into the circulation. Alternatively, the 
weak-positive result could be false. In this situation the test should be
repeated after a few weeks, or a DNA PCR could be performed for
confirmation.
< Testing within a cattery To determine whether FeLV-viraemic cats are 
in a cattery, pooled saliva samples can be tested by RNA PCR. Saliva
swabs from individual cats are put into tubes and shipped to the
laboratory, where they will be extracted, pooled and assayed; cooling is
not needed. The test is sensitive enough to detect a single infected cat
in a pool of up to 30 samples.31 While all viraemic cats are positive for
FeLV RNA in saliva, a few cats may be found that shed FeLV RNA in
saliva but are not (yet) viraemic or antigenaemic.32
Note that these detection methods do not identify all FeLV-infected animals,
possibly leading to an underestimation of the prevalence of infection. Low-
dose exposure to the virus may result in seroconversion during a presumed
abortive infection.33
Diagnosis of  FeLV infect ion
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viral loads; however, viraemia was not over-
come completely [EBM grade III].34,35
Good (recombinant) FeLV vaccines are
available, which protect from disease but not
from infection. The ABCD suggests that cats at
risk (eg, with access to outdoors) are primari-
ly vaccinated. Cats living in an apartment
with no contact with other cats may not need
to be vaccinated. Vaccination should take
place at 8–9 weeks, again at 12–13 weeks and
1 year later. Thereafter, vaccination frequency
can be lowered to an interval of 2–3 years. 
Feline immunodeficiency virus
infection
Feline immunodeficiency virus (FIV) 
infection may induce clinical signs of
immuno deficiency that lead to oppor-
tunistic infections or lymphomas,
although in some cats the clinical
signs are mild. A few studies have
shown that the survival time of
infected cats was not decreased;
such variable outcomes are likely a
result of the heterogeneity of viral
isolates as well as management prac-
tices. FIV-infected cats kept in single
cat households with regular veterinary
care are more likely to remain healthy than
those in multicat households lacking regular
health checks. Prompt supportive treatment
dramatically increases the survival time for
FIV-infected cats.  
The infection is usually diagnosed using in-
house serological assays to detect antibodies
against major viral proteins, and it is impor-
tant that such results are properly interpreted.
Situations where a confirmatory test should
be used are described in the box below.
Several laboratories offer PCR tests for the
diagnosis of FIV but these tests are not neces-
sarily more reliable than serological tests. PCR
tests are highly prone to contamination and
must be conducted under rigorous conditions
with appropriate controls to minimise false-
positive results. False-negative results may
arise in situations where the primers are not
homologous to the infecting field strain and,
therefore, infection is not detected. 
Few antiviral drugs are effective against FIV
and do not induce adverse side effects.
Treatment with nucleoside analogues that
inhibit the reverse transcriptase, such as AZT
or PMEA, may reduce clinical signs but these
drugs, as well as derivatives such as PMP-
DAP, induce anaemia. Bicyclams bind to the
FIV co-receptor molecule CXCR4, thereby
inhibiting viral replication. Treatment with the
bicyclam AMD3100 leads to a significant
decrease in proviral load in cats naturally
infected with FIV and may be a useful thera-
py, but this treatment should not be combined
with PMEA [EBM grade I].36
A whole inactivated virus vaccine has been
available commercially to veterinarians in the
USA since 2002, and in Australia and New
Zealand since 2004. However, its use is not
recommended in Europe by the ABCD since
the antibodies induced interfere with the 
serological diagnosis of infection. Also, the
vaccine has not proven effective against pri-
mary field strains of FIV circulating in Europe. 
Feline rabies
Rabies is still endemic in some middle and
east European countries, and in 2011 the total
number of animal cases in Europe was 5801,
mainly involving foxes (source WHO).
However, on very rare occasions isolated
rabies cases in companion animals appear
also in western European countries that are
considered as rabies free. Often the source of
these is illegal importation of a pet from
endemic areas.
Due to testing of pets for neutralising 
antibodies, which has been required by some
countries before entering their territory, 
interesting data have been published about
duration of the antibody response after 
vaccination. Though differences in efficacy
between some commercial rabies vaccines
used in Europe have been demonstrated,37–39
following a single vaccination these products
have been shown to induce in most animals a
titre above 0.5 IU/ml, the internationally
accepted threshold antibody level [EBM grade
III].37,38,40 In cats and dogs, the peak of rabies
neutralising antibodies is generally reached
4–8 weeks after the first immunisation [EBM
grade III].38 Nevertheless, the titre decreases
with time. When tested 6–12 months after the
first vaccination, about 8% of cats have a titre




The feline immunodeficiency guidelines
that this present article is updating were
published in J Feline Med Surg 2009; 11:
575–584. This update has been compiled by 
Margaret J Hosie. 
A confirmatory test for FIV infection is required in the following situations:
< In populations of cats of low FIV prevalence A positive result in a
young indoor cat may be a false positive, and should be confirmed using
a different test (eg, Western blot or virus isolation). 
< Kittens Young kittens may test seropositive owing to the persistence 
of maternally derived antibody and should be retested at 6 months to
confirm whether they are infected.
< Early stages of infection Seroconversion may be delayed for several
weeks to months following infection, especially in cats homed together
with FIV-infected cats.
< Terminal stages of infection In cats with immunodeficiency and high
viral burdens, antibody may be sequestered in virus–antibody
complexes, leading to false-negative results.
Test ing for  FIV infect ion
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another study involving thousands of
dogs tested 120–360 days post-vaccina-
tion, the proportion of animals with a
titre below 0.5 IU/ml was 12.6%, or
3.1%, depending on the vaccine
brand used [EBM grade III].37
There is increasing evidence that
the persistence of antibody after
the first rabies vaccination may be
much shorter than generally
believed, especially in dogs. It has
been demonstrated that antibody titres
fall below 0.5 IU/ml in almost 21% of
dogs within 4–6 months after a single vacci-
nation [EBM grade III],40 and in many puppies
it happens as early as after 56 or even 28 days
[EBM grade III].38 In another study the propor-
tion of dogs with titres below 0.5 IU/ml 
6 months after the first vaccination reached
30% and then stabilised at above 30% during
the next 6 months [EBM grade III].39 Thus, a
new regimen for rabies vaccination, consisting
of double primary vaccination with a short
interval of 7–10 days and a 1-year booster, has
been postulated.39 This procedure reduced the
proportion of cats developing a titre below 
0.5 IU/ml to almost zero, when tested within 6
months, and in dogs this proportion was also
significantly lower than in animals given a sin-
gle primary vaccination [EBM grade III].39
A non-adjuvanted recombinant rabies vac-
cine for cats was recently marketed in some
European and other countries. It has been
shown to induce immunity lasting 3 years
[EBM grade I].41 During efficacy studies it has
been observed that even two cats with a titre
at the time of challenge below 0.5 IU/ml 
survived without developing rabies, suggest-
ing that mechanisms other than induction of
antibody play a role in protection.41
Feline infectious peritonitis
The pathogenesis and epidemiology of feline
infectious peritonitis (FIP), a bone of contention
until recently, have been further elucidated.
The hypothesis of mutants arising in individ-
ual cats upon bursts of replication (eg, under
immune-suppressive stress) has been experi-
mentally corroborated and explains the
sporadic, non-epidemic occurrence of
FIP.42 Functional expression of one of
the non-structural proteins (3c) is
crucial for feline coronavirus (FCoV)
replication in the gut, but dispensa-
ble for systemic replication of the
feline infectious peritonitis virus
(FIPV) mutant. While intact in all
FCoVs, the 3c gene was found
mutated in >70% of FIPV strains – but
not in all, implying that mutation in 3c
is not the (single) cause of FIP.
Most cats with FIP had no detectable intes-
tinal FCoV and had seemingly cleared the pri-
mary infection. In those with detectable
intestinal FCoV, the virus always had an intact
3c and seemed to have been acquired by FCoV
superinfection.43 Apparently, 3c-inactivated
viruses replicate not at all – or only poorly – in
the gut, explaining the rare incidence of FIP
outbreaks. After experimental infection with
FIPV strains with an intact 3c gene, the virus
was shed in the faeces. Also, faecal virus from
these cats was not infectious for other cats.44
Sequencing of many different FIPV and
FCoV strains revealed two alternative codons
in the S gene that correlated with the FIP phe-
notype in >95% of cases. This again supports
the internal mutation theory and might also
be a basis for identifying the virulent FIPV
phenotype in cats suspected of having FIP.45
Chlamydophila felis infection
Chlamydophila felis is primarily an ocular
pathogen, causing both acute and chronic 
conjunctivitis. Serological surveys have shown
that infection is widespread in cats but 
most clinical cases occur in young cats under 
9 months of age, particularly pedigree 
kittens from multicat households.
Conjunc tivitis is a common reason for
presentation of cats to practitioners
and Chlamydophila is the single most
common infectious cause and pos-
sibly the most common cause over-
all. The conjunctivitis is usually
bilateral but may be unilateral early
in infection or in chronic cases.
Chlamydophila will not usually cause
corneal lesions.
PCR testing of ocular swabs is now the
preferred method of diagnosis. Care is neces-
sary in collecting swabs as the organism is
essentially intracellular and some conjunctival
cellular material is required to optimise the
chance of detecting the organism.
While other antibiotics, such as fluoro-
quinolones, have some activity against
Chlamydophila, systemic doxycycline (10
mg/kg q24h) is regarded as the treatment of
choice [EBM grade III] and should be contin-
ued for a minimum of 3 weeks to ensure that
the infection is eliminated and signs do not
recur when treatment is stopped. Local ocular
preparations to relieve ocular inflammation
may also be beneficial.
Both inactivated and modified-live vaccines
are available to assist in control. These are
only available as part of multivalent vaccines.
Both types of vaccines will prevent or reduce
the severity of clinical signs but do not pre-
vent infection. These are not always included




The feline rabies guidelines that this
present article is updating were published in
J Feline Med Surg 2009; 11: 585–593. 




on prevention and management
The feline infectious peritonitis guidelines
that this present article is updating were
published in J Feline Med Surg 2009; 11:
594–604. This update has been compiled by
Herman Egberink. 
Chlamydophila felis
infection: ABCD guidelines on
prevention and management
The Chlamydophila felis infection
guidelines that this present article is
updating were published in J Feline Med
Surg 2009; 11: 605–609. This update has
been compiled by Tim Gruffydd-Jones. 
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cats but may be particularly indicated in cat-
teries with endemic infection or in high-risk
(most frequently multicat) situations such 
as breeding catteries and rescue shelters.
Chlamydial polymorphic membrane proteins
have been identified as immunodominant and
considered as potential serodiagnostic anti-
gens and novel vaccine candidates.46
Bordetella bronchiseptica
infection in cats
Bordetella bronchiseptica is primarily a respira-
tory pathogen. The bacterium may particular-
ly play a role in multicat environments, where
other factors like overcrowding, stress and
poor hygienic conditions exist. In general,
clinical signs are mild, although pneumonia
has been reported, especially in young kittens
less than 10 weeks old.
B bronchiseptica is shed with oral and nasal
secretions of infected cats. After experimental
infection, B bronchiseptica could be isolated for
19 weeks after infection. Transmission is
through direct contact, although indirect
transmission cannot be excluded. However, 
B bronchiseptica is susceptible to common dis-
infectants. Epidemiological studies suggest
that dog-to-cat transmission occurs. Also, a
few reports describe cats as a possible source
of infection of immunocompromised human
patients. It is therefore justified to consider 
B bronchiseptica as a rare but potential zoo notic
infection.47,48
For a diagnosis of B bronchiseptica infection,
both bacterial culture and PCR are available. 
B bronchiseptica can be isolated from oropha-
ryngeal or nasal secretions; alternatively,
transtracheal wash/bronchoalveolar lavage
are used. Nasal swabs were shown to be more
often positive then oropharyngeal swabs.49
Both methods lack sensitivity.
Antibacterial therapy is indicated, including
in cases with mild clinical signs, to prevent
more severe disease due to colonisation of the
lower respiratory tract. The choice of antibiotic
should be based on antibiotic sensitivity testing.
If not available, tetracyclines, and in particular
doxycycline, are the antibiotics of choice.
Resistance has been detected against 
clavulanate-potentiated amoxicillin, 
and to a higher extent against ampi-
cillin and trimethoprim [EBM grade
III]. Supportive therapy and intense
nursing care are required in severe-
ly affected animals. 
The control of B bronchiseptica
infections requires similar measures
as used for other respiratory
pathogens (ie, FCV and FHV). These
are aimed at preventing spread of the
infectious agents and reducing their con-
centration in the environment. An intranasal
modified-live vaccine is available but not con-
sidered a core vaccine. Vaccination should be
limited to cats living in high-risk environments
such as shelters and boarding catteries, and
where B bronchiseptica has been identified as
the problem. The modified-live vaccine is
licensed for use as a single vaccination with
annual boosters. Interestingly, vaccination with
an intranasal live FCV and FHV vaccine also
reduced the signs of an experimental B bron-
chiseptica infection [EBM grade III].50 Whether
this non-specific effect is also beneficial for pro-
tection under field conditions is unknown.
Influenza A virus infection in cats
Felids can be naturally and experimentally
infected with influenza A viruses; outcomes
range from subclinical infection to fatal dis-
ease. The virulence of H5N1 highly pathogen-
ic avian virus strains for the domestic cat was
established at the very beginning of the
avian flu epidemics in Asia. During the
same period, infection of household
cats and outbreaks of fatal disease in
tigers and leopards were reported
from Thailand. Then, in Europe,
three cats were found dead on the
island of Rügen, Germany. The
susceptibility of the cat to influen-
za A viruses was confirmed during
the H1N1 pandemic in 2009/2010;
indeed, several cases of respiratory
disease in domestic cats were linked to
the pandemic H1N1 virus.51 Luckily nei-
ther H5N1 nor H1N1 virus infections spread
among domestic cats in Europe.52,53
Cats can be infected via the intratracheal
and oral routes and, for H5N1 virus, by feed-
ing them infected chickens. Infection with the
H5N1 virus may occur through contact with
infected birds, and with H1N1 likely with
infected owners. Therefore, a cat living in a
household with human cases of influenza is at
risk. To date, no cat-to-person transmission
has been reported, but the risk for persons can
presently not be predicted.
If influenza in cats is suspected, their case
histories need to be recorded. Differential
diagnosis should exclude other infections
leading to similar systemic and respiratory
signs, including infections with FHV, FCV and
B bronchiseptica. Diagnosis should always be
confirmed by laboratory testing. In the
absence of specific preventive measures, the
risk of a cat acquiring an influenza A virus
infection must be minimised through 
management measures. Especially for H1N1,
but also for other human influenza A virus
infections, patients must be advised to avoid
physical contact with cats.
Bordetella
bronchiseptica infection
in cats: ABCD guidelines on
prevention and management
The Bordetella bronchiseptica infection in
cats guidelines that this present article is
updating were published in J Feline Med
Surg 2009; 11: 610–614. This update has
been compiled by Herman Egberink. 
H5N1 avian influenza in
cats: ABCD guidelines on
prevention and management
The H5N1 avian influenza in cats
guidelines that this present article is
updating were published in J Feline Med
Surg 2009; 11: 615–618. This update has
been compiled by Etienne Thiry. 
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